Does the media prefer ANAB or LRMR?

In the previous week, AnaptysBio had 10 more articles in the media than Larimar Therapeutics. MarketBeat recorded 12 mentions for AnaptysBio and 2 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.71 beat AnaptysBio's score of 1.15 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Larimar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer LRMR or VIR?

In the previous week, Vir Biotechnology had 8 more articles in the media than Larimar Therapeutics. MarketBeat recorded 10 mentions for Vir Biotechnology and 2 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.71 beat Vir Biotechnology's score of 1.30 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Vir Biotechnology 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LRMR or ABSI?

In the previous week, Absci had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 8 mentions for Absci and 2 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.71 beat Absci's score of 1.26 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Absci 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LRMR or MAZE more profitable?

Maze Therapeutics' return on equity of -34.94% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -137.39% -97.65% Maze Therapeutics N/A -34.94% -30.18%

Does the media refer more to LRMR or MAZE?

In the previous week, Maze Therapeutics had 12 more articles in the media than Larimar Therapeutics. MarketBeat recorded 14 mentions for Maze Therapeutics and 2 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.71 beat Maze Therapeutics' score of 1.42 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Maze Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, FBRX or LRMR?

Forte Biosciences is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.65 N/A Larimar Therapeutics N/A N/A -$165.67M -$1.95 N/A

Is FBRX or LRMR more profitable?

Forte Biosciences' return on equity of -94.82% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -94.82% -77.68% Larimar Therapeutics N/A -137.39% -97.65%

Does the media prefer FBRX or LRMR?

In the previous week, Forte Biosciences had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 8 mentions for Forte Biosciences and 2 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.71 beat Forte Biosciences' score of 0.80 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Larimar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Larimar Therapeutics (LRMR) Competitors

$4.01 -0.04 (-0.99%)

As of 08/28/2026 04:00 PM Eastern

Compare

LRMR vs. ANAB, VIR, ABSI, MAZE, and FBRX

Should you buy Larimar Therapeutics stock or one of its competitors? Larimar Therapeutics's main competitors and comparable companies include AnaptysBio (ANAB), Vir Biotechnology (VIR), Absci (ABSI), Maze Therapeutics (MAZE), and Forte Biosciences (FBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Larimar Therapeutics compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

AnaptysBio has higher revenue and earnings than Larimar Therapeutics. AnaptysBio is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	7.10	-$13.23M	-$1.08	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A

Larimar Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Larimar Therapeutics	N/A	-137.39%	-97.65%

In the previous week, AnaptysBio had 10 more articles in the media than Larimar Therapeutics. MarketBeat recorded 12 mentions for AnaptysBio and 2 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.71 beat AnaptysBio's score of 1.15 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Larimar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

91.9% of Larimar Therapeutics shares are owned by institutional investors. 31.5% of AnaptysBio shares are owned by insiders. Comparatively, 4.0% of Larimar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AnaptysBio has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

AnaptysBio presently has a consensus price target of $80.00, indicating a potential upside of 42.15%. Larimar Therapeutics has a consensus price target of $11.67, indicating a potential upside of 190.94%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Larimar Therapeutics is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Summary

AnaptysBio and Larimar Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to Vir Biotechnology?

Larimar Therapeutics (NASDAQ:LRMR) and Vir Biotechnology (NASDAQ:VIR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 4.0% of Larimar Therapeutics shares are held by insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Larimar Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Vir Biotechnology	$302.59M	6.06	-$437.99M	-$1.86	N/A

In the previous week, Vir Biotechnology had 8 more articles in the media than Larimar Therapeutics. MarketBeat recorded 10 mentions for Vir Biotechnology and 2 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.71 beat Vir Biotechnology's score of 1.30 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Vir Biotechnology	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

Larimar Therapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

Larimar Therapeutics currently has a consensus price target of $11.67, suggesting a potential upside of 190.94%. Vir Biotechnology has a consensus price target of $21.57, suggesting a potential upside of 99.18%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Larimar Therapeutics beats Vir Biotechnology on 9 of the 15 factors compared between the two stocks.

How does Larimar Therapeutics compare to Absci?

Larimar Therapeutics (NASDAQ:LRMR) and Absci (NASDAQ:ABSI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Absci shares are owned by institutional investors. 4.0% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Absci shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Larimar Therapeutics has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Absci	-7,756.38%	-61.71%	-54.52%

Absci has higher revenue and earnings than Larimar Therapeutics. Absci is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Absci	$2.80M	533.83	-$115.18M	-$0.80	N/A

In the previous week, Absci had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 8 mentions for Absci and 2 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.71 beat Absci's score of 1.26 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Absci	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Absci has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

Larimar Therapeutics presently has a consensus price target of $11.67, indicating a potential upside of 190.94%. Absci has a consensus price target of $13.43, indicating a potential upside of 54.17%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Larimar Therapeutics is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Absci beats Larimar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to Maze Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Larimar Therapeutics presently has a consensus price target of $11.67, indicating a potential upside of 190.94%. Maze Therapeutics has a consensus price target of $66.00, indicating a potential upside of 140.52%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Larimar Therapeutics is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08

91.9% of Larimar Therapeutics shares are owned by institutional investors. 4.0% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Maze Therapeutics' return on equity of -34.94% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Maze Therapeutics	N/A	-34.94%	-30.18%

In the previous week, Maze Therapeutics had 12 more articles in the media than Larimar Therapeutics. MarketBeat recorded 14 mentions for Maze Therapeutics and 2 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.71 beat Maze Therapeutics' score of 1.42 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Maze Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maze Therapeutics has higher revenue and earnings than Larimar Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Maze Therapeutics	$20M	76.21	-$131.12M	-$2.52	N/A

Larimar Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market.

Summary

Maze Therapeutics beats Larimar Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Larimar Therapeutics compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Forte Biosciences' return on equity of -94.82% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
Larimar Therapeutics	N/A	-137.39%	-97.65%

Forte Biosciences currently has a consensus price target of $71.67, indicating a potential downside of 6.91%. Larimar Therapeutics has a consensus price target of $11.67, indicating a potential upside of 190.94%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Larimar Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by company insiders. Comparatively, 4.0% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Forte Biosciences has a beta of 2.62, indicating that its stock price is 162% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Forte Biosciences is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A

In the previous week, Forte Biosciences had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 8 mentions for Forte Biosciences and 2 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.71 beat Forte Biosciences' score of 0.80 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Larimar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Larimar Therapeutics beats Forte Biosciences on 8 of the 14 factors compared between the two stocks.

Get Larimar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LRMR vs. The Competition

Export

Metric	Larimar Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$416.57M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-2.06	11.62	273.16	25.45
Price / Sales	N/A	1,295.89	605.01	76.63
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	3.26	16.53	12.98	6.14
Net Income	-$165.67M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-4.07%	-0.31%	0.13%	-0.80%
1 Month Performance	4.70%	9.80%	7.08%	4.13%
1 Year Performance	10.77%	55.66%	24.67%	15.17%

Larimar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LRMR Larimar Therapeutics	3.7171 of 5 stars	$4.01 -1.0%	$11.67 +190.9%	+10.8%	$416.57M	N/A	N/A	30	Positive News
ANAB AnaptysBio	3.0175 of 5 stars	$58.44 +1.2%	$82.00 +40.3%	+176.8%	$1.71B	$234.60M	N/A	100	News Coverage Positive News Upcoming Earnings Analyst Downgrade
VIR Vir Biotechnology	2.5494 of 5 stars	$9.91 +1.3%	$20.63 +108.1%	+119.2%	$1.65B	$68.56M	N/A	580	News Coverage Positive News
ABSI Absci	2.8783 of 5 stars	$8.84 -7.4%	$13.43 +51.9%	+264.4%	$1.64B	$1.56M	N/A	210	Gap Up
MAZE Maze Therapeutics	2.4951 of 5 stars	$29.60 +0.6%	$66.00 +123.0%	+89.4%	$1.63B	$167.50M	N/A	121	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LRMR) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Larimar Therapeutics (LRMR) Competitors

LRMR vs. ANAB, VIR, ABSI, MAZE, and FBRX

How does Larimar Therapeutics compare to AnaptysBio?

Summary

How does Larimar Therapeutics compare to Vir Biotechnology?

Summary

How does Larimar Therapeutics compare to Absci?

Summary

How does Larimar Therapeutics compare to Maze Therapeutics?

Summary

How does Larimar Therapeutics compare to Forte Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Larimar Therapeutics (LRMR) Competitors

LRMR vs. ANAB, VIR, ABSI, MAZE, and FBRX

How does Larimar Therapeutics compare to AnaptysBio?

Which has better earnings and valuation, ANAB or LRMR?

Is ANAB or LRMR more profitable?

Does the media prefer ANAB or LRMR?

Do insiders & institutionals believe in ANAB or LRMR?

Which has more volatility and risk, ANAB or LRMR?

Do analysts recommend ANAB or LRMR?

Summary

How does Larimar Therapeutics compare to Vir Biotechnology?

Do insiders and institutionals have more ownership in LRMR or VIR?

Which has better valuation & earnings, LRMR or VIR?

Does the media prefer LRMR or VIR?

Which has more volatility and risk, LRMR or VIR?

Is LRMR or VIR more profitable?

Do analysts prefer LRMR or VIR?

Summary

How does Larimar Therapeutics compare to Absci?

Do institutionals & insiders believe in LRMR or ABSI?

Is LRMR or ABSI more profitable?

Which has preferable earnings & valuation, LRMR or ABSI?

Does the media refer more to LRMR or ABSI?

Which has more risk & volatility, LRMR or ABSI?

Do analysts rate LRMR or ABSI?

Summary

How does Larimar Therapeutics compare to Maze Therapeutics?

Do analysts prefer LRMR or MAZE?

Do insiders & institutionals have more ownership in LRMR or MAZE?

Is LRMR or MAZE more profitable?

Does the media refer more to LRMR or MAZE?

Which has preferable valuation & earnings, LRMR or MAZE?

Which has more volatility and risk, LRMR or MAZE?

Summary

How does Larimar Therapeutics compare to Forte Biosciences?

Is FBRX or LRMR more profitable?

Do analysts recommend FBRX or LRMR?

Do insiders and institutionals believe in FBRX or LRMR?

Which has more risk and volatility, FBRX or LRMR?

Which has higher valuation & earnings, FBRX or LRMR?

Does the media prefer FBRX or LRMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools